Leadership

Mr. Kelly is executive vice president, chief financial officer (CFO) and treasurer with responsibility for finance, investor relations and information technology. Prior to joining Novavax, Mr. Kelly held CFO roles with Supernus Pharmaceuticals and Vanda Pharmaceuticals, in addition to key finance roles at MedImmune (now AstraZeneca), Biogen and Aetna. Mr. Kelly earned a Bachelor of Science in Business Administration from the University of Vermont, a Master of Business Administration from Cornell University, and is a Chartered Financial Analyst (CFA^_®) charterholder.